Ionis, Akcea boosted by a positive PhII for their Novartis castoff cardio drug — and they plan to push ahead into pivotals
Late last year Novartis abandoned a cardio drug from Ionis’ spinoff Akcea just after the pharma giant snapped up inclisiran, going the RNAi way …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
